MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-28
DOI
10.1038/s41598-019-39453-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer
- (2017) Aijun Yang et al. Oncology Letters
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2
- (2016) XIAOJUAN ZHAO et al. Oncology Letters
- miR-494-3p is a novel tumor driver of lung carcinogenesis
- (2016) Alice Faversani et al. Oncotarget
- MiR-494 Inhibits Epithelial Ovarian Cancer Growth by Targeting c-Myc
- (2016) Jialing Yuan et al. MEDICAL SCIENCE MONITOR
- Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer
- (2015) Guangmei Mao et al. ANGIOGENESIS
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- miR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells
- (2015) Xue-tao Li et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment
- (2015) Bing Feng et al. CLINICAL SCIENCE
- Maintenance therapy in non-small cell lung cancer
- (2015) Giovenzio Genestreti et al. Expert Review of Anticancer Therapy
- MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD
- (2015) Jie Chai et al. IUBMB LIFE
- miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN
- (2015) KAI LIU et al. ONCOLOGY REPORTS
- Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer
- (2015) Juan Wang et al. TUMOR BIOLOGY
- miR-494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN
- (2014) HAI-BING SUN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc
- (2014) Weiling He et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Caspase-2 as a tumour suppressor
- (2013) J Puccini et al. CELL DEATH AND DIFFERENTIATION
- MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer
- (2013) Lionel Lim et al. HEPATOLOGY
- MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation
- (2012) G. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells
- (2011) H. Ohdaira et al. CELL PROLIFERATION
- MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint
- (2011) Alexandru V. Olaru et al. HEPATOLOGY
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
- (2011) Ana-Maria Florea et al. Cancers
- MicroRNA-494 Targeting Both Proapoptotic and Antiapoptotic Proteins Protects Against Ischemia/Reperfusion-Induced Cardiac Injury
- (2010) Xiaohong Wang et al. CIRCULATION
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
- (2010) Alex Chang LUNG CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started